Artiva Biotherapeutics (NASDAQ:ARTV) Raised to Hold at Wall Street Zen

Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research firms also recently weighed in on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $11.27 on Friday. Artiva Biotherapeutics has a 1-year low of $2.22 and a 1-year high of $14.53. The business has a 50-day moving average of $9.36 and a 200-day moving average of $7.77. The company has a market capitalization of $278.59 million, a price-to-earnings ratio of -3.42 and a beta of 2.16.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). Research analysts expect that Artiva Biotherapeutics will post -2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. bought 24,944 shares of the business’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $9.93 per share, with a total value of $247,693.92. Following the completion of the acquisition, the director directly owned 17,329,570 shares of the company’s stock, valued at approximately $172,082,630.10. The trade was a 0.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have bought 1,965,251 shares of company stock worth $16,188,035 and have sold 53,040 shares worth $477,890. 1.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. State of Wyoming acquired a new position in Artiva Biotherapeutics during the 2nd quarter valued at approximately $45,000. Bank of America Corp DE grew its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the second quarter worth $53,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics in the second quarter worth $58,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.